An interventional study of Systemic anticancer therapy and Surgery in Non-small Cell Lung Cancer (NSCLC) and Stage IV, sponsored by Swiss Cancer Institute. Recruiting at 7 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Swiss Cancer Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland — 42 open to participants now, 67 under way, 33 of them phase 3. Carcinoma, Non-Small-Cell Lung · Switzerland.
Among the 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland, this one is the 112th largest by planned enrollment of the 173 interventional ones that give a count, is one of 11 that started in 2024, is one of 6 with no phase, reaches primary completion later than 29 of the 66 other live ones, and was the 148th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →42 of the 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland are open now. Recruiting first, the newest first:
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Swiss Cancer Institute · Sites in Switzerland
Ages 70+
Orion Corporation, Orion Pharma · Sites in Switzerland, United States, Denmark and 4 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Switzerland, United States, Argentina and 29 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
186 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 70 · Phase 3 83 · Phase 4 4
First in 1995; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is above the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 290 across the 173 interventional studies, 304 across the 9 observational. Of the 108 that completed or were terminated, 62 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 186 have an industry lead sponsor. The 10 most frequent:
Swiss Cancer Institute is the lead sponsor of 27 studies on the registry; 12 are open to participants now.
Swiss Cancer Institute has 8 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
13 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06140836Phase 3Bristol-Myers SquibbA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | 2027-02-16 |
| NCT05522660Phase 3ETOP IBCSG Partners FoundationImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer | 2027-06 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06452277Phase 3BayerA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | 2027-10-28 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 13 to your calendar (.ics) → With an account.
Among the 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Most patients are already at an advanced stage when they are diagnosed with lung cancer, meaning the cancer has already spread outside the lungs and formed metastases. The current standard of care at this stage is systemic anticancer therapy, such as chemotherapy, immunotherapy to boost the body's immune response, or targeted therapy that directly hinders tumor growth. This study aims to find out whether it is better if, after a good response to standard therapy, the remaining main tumor and metastases are additionally treated by surgery and/or radiotherapy.
This study aims to find out whether, after a good response to standard therapy, it is better if the main tumor and all remaining metastases are additionally treated by surgery and/or radiotherapy. This intervention is called local ablative therapy (LAT). There is evidence that LAT may prolong the time to cancer progression (progression-free survival, PFS) or lead to longer survival. Currently, patients who respond to initial standard therapy are not routinely offered LAT. If the results are positive, this could change the current standard of practice.
The benefit of a therapy is not determined by PFS or survival alone, but also by its impact on quality of life. Side effects, pain, fatigue, nausea or long hospital stays can reduce the benefit from the patient's point of view. Quality of life, assessed with patient-reported outcome measures (PROMs), is therefore a co-primary endpoint, tested hierarchically after PFS.
All patients first receive 3 cycles or 3 months of standard first-line systemic therapy; a 4th bridging cycle is allowed until randomization. Restaging with contrast-enhanced (FDG-PET-)CT and brain MRI is performed 7 to 28 days after the last treatment cycle. Patients with partial response or stable disease and an (induced) oligometastatic or oligopersistent state are randomized 1:1, using minimization, to LAT plus standard systemic therapy or to standard systemic therapy alone. Minimization factors are country, targeted therapy (yes/no), response to first-line therapy, and definitive local treatment of brain metastases before inclusion (yes/no).
The study will enroll 128 patients at Swiss and international hospitals. Each patient is followed for at least 24 months after randomization.
The criteria were revised on the registry on Nov 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial. The inclusion criteria apply irrespective of the tumor burden at the time of primary diagnosis, before initiation of systemic therapy. Treatment of upfront or after an induction phase of standard systemic therapy is done according to the standard practice of the treating center.
Exclusion Criteria:
The presence of any one of the following exclusion criteria at screening will lead to exclusion of the participant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients receive standard first-line systemic therapy according to the molecular analysis of the diagnostic biopsy, per the standard of the treating center. After randomization, patients additionally undergo LAT of the primary tumor and all measurable residual metastases (except PET-negative bone metastases): complete surgical resection of the primary tumor with mediastinal lymph node sampling and/or radical radiotherapy (preferably stereotactic body radiotherapy, SBRT), and surgery and/or SBRT of the metastases. The first LAT is performed within 1 to 35 days after randomization. Choice and sequence of LAT (primary tumor versus metastases) are decided by the local multidisciplinary tumor board (MDT) after interdisciplinary counseling of the patient. Systemic anticancer therapy then continues as standard of care: chemotherapy, chemo-immunotherapy or immunotherapy restarts at the earliest 14 days after LAT; targeted therapy continues throughout.
Other: Systemic anticancer therapy · Other: Surgery · Radiation: Radiotherapy
Patients receive systemic anticancer therapy alone (chemotherapy, chemo-immunotherapy, immunotherapy alone, or targeted therapy), per the standard of the treating center. Local ablative treatment is not allowed. Assigned interventions: Other: Systemic anticancer therapy
Other: Systemic anticancer therapy
The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.
Also known as: Systemic therapy
Surgery
Radiotherapy
Progression-free survival (PFS): superiority of local ablative therapy (LAT) plus standard of care (SoC) versus SoC alone
PFS is defined as the time from randomization to first disease progression or death from any cause, analysed by intention-to-treat. Progression is assessed locally by regular clinical examinations and imaging (contrast-enhanced (FDG-PET-)CT of chest and abdomen, and brain MRI as clinically indicated) according to RECIST 1.1 / iRECIST.
Time frame: up to 24 months after randomization
Quality of life (QoL): non-inferiority of LAT plus SoC versus SoC alone, measured with the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) index score
The EQ-5D-5L covers five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels from 1 (no problems) to 5 (extreme problems). Index scores are calculated with the German EQ-5D-5L value set. Non-inferiority is shown if the upper limit of the 2-sided 95% confidence interval of the between-group difference lies below the margin of 0.1. QoL is tested only if PFS superiority is shown (hierarchical testing).
Time frame: 6 months after randomization
EORTC QLQ-C30 Global Health Status/Quality of Life Score
Global health status/QoL scale of the EORTC QLQ-C30, scored 0-100; higher scores indicate better quality of life. Compared between treatment groups.
Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization
EORTC QLQ-LC13 Symptom Scale Scores
Lung cancer-specific symptom scales of the EORTC QLQ-LC13, each scored 0-100; higher scores indicate more symptoms. Compared between treatment groups.
Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization
EQ-5D-5L Index Score Over Time
EQ-5D-5L index score calculated with the German valuation algorithm; higher scores indicate better quality of life. Compared between treatment groups.
Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization
EQ-5D Visual Analogue Scale (EQ VAS) Score
Self-rated overall health on the EQ VAS of the EQ-5D-5L, scored 0 (worst imaginable health) to 100 (best imaginable health). Compared between treatment groups.
Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization
FACT-L Total Score
Functional Assessment of Cancer Therapy - Lung total score, covering physical, social/family, emotional and functional well-being and the lung cancer subscale; range 0-136, higher scores indicate better quality of life. Compared between treatment groups.
Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization
Agreement Between Quality of Life Reported in the "My Cancer Companion" App and PROM Scores
Optional use of the mobile app with daily or as frequent as possible data entry, compared with PROMs completed at the scheduled visits.
Time frame: up to 24 months after randomization
Number of Participants With Grade ≥ 3 Surgical Complications (Clavien-Dindo)
Participants undergoing surgical resection with at least one major surgical complication of Clavien-Dindo grade ≥ 3, including the name of the event.
Time frame: up to 24 months after randomization
Number of Participants With Grade ≥ 3 Radiotherapy-Related Adverse Events (CTCAE v5.0)
Participants receiving radiotherapy with at least one radiotherapy-related adverse event of CTCAE version 5.0 grade ≥ 3, including the name of the event.
Time frame: up to 24 months after randomization
Number of Participants With Grade ≥ 3 Systemic Therapy-Related Adverse Events (CTCAE v5.0)
Participants receiving systemic therapy with at least one systemic therapy-related adverse event of CTCAE version 5.0 grade ≥ 3, including the name of the event.
Time frame: up to 24 months after randomization
Number of Serious Adverse Reactions (SARs)
Count of serious adverse reactions related to surgery, radiotherapy or systemic therapy per treatment group, compared as a rate ratio (Poisson regression adjusted for the minimization variables).
Time frame: up to 24 months after randomization
Quality-Adjusted Life Years (QALYs)
Area under the EQ-5D-5L index score curve across all time points, compared between treatment groups.
Time frame: from screening until 24 months after randomization
Healthcare Utilization
Condition-specific healthcare utilization extracted from the electronic patient charts of the enrolling hospital, complemented by patient-reported use of healthcare services elsewhere at each trial visit. Compared between treatment groups.
Time frame: from signing informed consent until 24 months after randomization
Condition-Specific Healthcare Costs
From screening up to 24 months after randomization
Time frame: Condition-specific healthcare costs in Swiss francs (CHF), including the cost of the study intervention, from a Swiss healthcare system perspective, based on hospital accounting data and published Swiss unit costs. Compared between treatment groups.
Incremental Cost-Effectiveness Ratio (ICER) of the LAT Strategy
Difference in costs divided by difference in QALYs between LAT plus SoC and SoC alone, in CHF per QALY gained. Calculated if neither strategy is dominant.
Time frame: up to 24 months after randomization
Overall Survival (OS)
Time from randomization to death from any cause. Date and cause of death are recorded.
Time frame: From randomization through study completion, up to 48 months
Objective Response Rate of the Primary Tumor
Percentage of participants with complete or partial response of the primary tumor, assessed locally by contrast-enhanced FDG-PET-CT according to RECIST 1.1 / iRECIST.
Time frame: at screening (restaging after first-line therapy) and 3, 6, 12, 18 and 24 months after randomization
Objective Response Rate of Metastases
Percentage of participants with complete or partial response of metastases, assessed locally by contrast-enhanced FDG-PET-CT of chest and abdomen and brain MRI according to RECIST 1.1 / iRECIST.
Time frame: at screening (restaging after first-line therapy) and 3, 6, 12, 18 and 24 months after randomization
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Nov 2027, 44 months after the start.
Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 44 months is below that.
Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.
Start moved once since we started tracking on Sep 25, 2026: Dec 2023 → Feb 2024, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Swiss Cancer Institute